dialysis membrane; bone turnover markers; hemodiafiltration; hemodialysis
Abstract :
[en] Background. Chronic kidney disease (CKD) is associated with disturbances in mineral and bone metabolism, increasing fracture risk, particularly in advanced stages. Bone turnover markers (BTMs) such as bone alkaline phosphatase (BALP) and tartrate‐resistant acid phosphatase 5b (TRACP5b), as well as collagen‐derived markers including intact form of procollagen type I amino‐terminal propeptide (iPINP) and β‐cross‐linked C‐terminal telopeptide of type I collagen (β‐CTX‐I), are recommended to assess bone turnover. Although some BTMs are considered stable and independent of renal function, their behavior during dialysis sessions remains unclear. Methods. To assess the impact of dialysis techniques and membrane types, serum samples were collected pre‐ and post‐dialysis. BTM concentrations were analyzed using nonparametric statistics, and the clinical relevance of the observed changes was evaluated using the least significant change (LSC) thresholds. Results. BALP and TRACP5b showed minor fluctuations post‐dialysis, with changes remaining below their clinical significance thresholds. iPINP also showed limited variability. In contrast, β‐CTX‐I decreased significantly after hemodialysis, especially using high‐permeability membranes, with changes exceeding the LSC threshold. Conclusion. These findings suggest that BALP, TRACP5b, and PINP demonstrate robustness as BTMs in CKD patients undergoing dialysis. However, β‐CTX‐I is markedly affected by dialysis parameters and should be interpreted cautiously in this context.
Research Center/Unit :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Human health sciences: Multidisciplinary, general & others
Author, co-author :
Mackowiak, Alix ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)
DUBOIS, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie
Grifnée, Elodie ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Demeuse, Justine ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Le Goff, Caroline ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Loberg Haarhaus, Mathias; Division of Renal Medicine, Department of Clinical Sciences, Intervention and Technology Karolinska Institutet, University Hospital of Karolinska Stockholm Sweden ; Diaverum Sweden Malmö Sweden
Magnusson, Per; Department of Clinical Chemistry Linköping University Linköping Sweden ; Department of Biomedical and Clinical Sciences Linköping University Linköping Sweden
Jørgensen, Hanne Skou ; Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group University of Leuven Leuven Belgium ; Department of Clinical Medicine University of Aarhus Aarhus Denmark ; Department of Nephrology University Hospital of Aalborg Aalborg Denmark
Evenepoel, Pieter; Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group University of Leuven Leuven Belgium ; Department of Nephrology and Renal Transplantation University of Leuven Leuven Belgium
Delanaye, Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Language :
English
Title :
Changes in Bone Turnover Markers Associated With a Single Dialysis Session
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, “KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),” Kidney International. Supplement 76, no. 113 (2009): S1–S130, https://doi.org/10.1038/ki.2009.188.
D. Smout, H. S. Jørgensen, E. Cavalier, and P. Evenepoel, “Clinical Utility of Bone Turnover Markers in Patients With Chronic Kidney Disease,” Current Opinion in Nephrology and Hypertension 31, no. 4 (2022): 332–338, https://doi.org/10.1097/MNH.0000000000000798.
A. Nizet, E. Cavalier, P. Stenvinkel, M. Haarhaus, and P. Magnusson, “Bone Alkaline Phosphatase: An Important Biomarker in Chronic Kidney Disease – Mineral and Bone Disorder,” Clinica Chimica Acta 501 (2020): 198–206, https://doi.org/10.1016/j.cca.2019.11.012.
K. Shidara, M. Inaba, S. Okuno, et al., “Serum Levels of TRAP5b, a New Bone Resorption Marker Unaffected by Renal Dysfunction, as a Useful Marker of Cortical Bone Loss in Hemodialysis Patients,” Calcified Tissue International 82, no. 4 (2008): 278–287, https://doi.org/10.1007/s00223-008-9127-4.
P. Delanaye, J. C. Souberbielle, M. H. Lafage-Proust, G. Jean, and E. Cavalier, “Can We Use Circulating Biomarkers to Monitor Bone Turnover in CKD Haemodialysis Patients? Hypotheses and Facts,” Nephrology, Dialysis, Transplantation 29, no. 5 (2014): 997–1004, https://doi.org/10.1093/ndt/gft275.
M. G. Vervloet and V. M. Brandenburg, “Circulating Markers of Bone Turnover,” Journal of Nephrology 30, no. 5 (2017): 663–670, https://doi.org/10.1007/s40620-017-0408-8.
E. Cavalier, P. U. Torres, B. E. Dubois, et al., “Impact of the Type of Dialysis Membranes on the Circulating Concentration of Markers of Vitamin D Metabolism,” International Journal of Artificial Organs 40, no. 2 (2017): 43–47, https://doi.org/10.5301/ijao.5000565.
EFLM Biological Variation, accessed February 4, 2025, https://biologicalvariation.eu/.
M. Gomez, M. Arias-Guillén, and F. Maduell, “An Extended Kinetic Model-Based Correction Factor Equation to Account Hemodialysis Post-Treatment Hemoconcentration,” International Journal of Artificial Organs 46, no. 5 (2023): 314–317, https://doi.org/10.1177/03913988231160803.
M. Ketteler, G. A. Block, P. Evenepoel, et al., “Executive Summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: What's Changed and Why It Matters,” Kidney International 92, no. 1 (2017): 26–36, https://doi.org/10.1016/j.kint.2017.04.006.